EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Reporter Gene mRNA with Cap 1 Structure and Enhanced Stability

Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a synthetic messenger RNA encoding the monomeric red fluorescent protein mCherry, derived from DsRed of Discosoma spp. (Shaner 2004, Nature Methods). The mRNA is approximately 996 nucleotides in length and provided at ~1 mg/mL in 1 mM sodium citrate buffer (pH 6.4). It features an enzymatically added Cap 1 structure, incorporates 5-methylcytidine triphosphate (5mCTP) and pseudouridine triphosphate (ψUTP) for increased stability and immune evasion, and includes a poly(A) tail for translation efficiency (APExBIO product page). The product is optimized as a reporter gene for cell biology research, with proven capability to suppress RNA-mediated innate immune activation (Roach 2024). It should be stored at or below −40°C to maintain stability and functionality.

Biological Rationale

Reporter gene mRNAs are essential for visualizing and quantifying gene expression and protein localization in live-cell and in vivo systems (Giepmans 2006, Science). mCherry is a widely used red fluorescent protein with excitation and emission maxima at 587 nm and 610 nm, respectively, providing a robust molecular marker for imaging (FPbase). Incorporation of Cap 1 structure into mRNA enhances translation efficiency and mimics native mammalian mRNA, reducing detection by pattern recognition receptors (PRRs). Modified nucleotides such as 5mCTP and ψUTP further suppress innate immune responses and prolong mRNA stability, allowing for more sustained reporter expression (Roach 2024).

Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) leverages multiple biochemical features to optimize fluorescent protein expression:

• Cap 1 Structure: Enzymatically added using Vaccinia virus Capping Enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2′-O-Methyltransferase. This structure increases translation efficiency by enhancing recognition by eukaryotic initiation factors and mimics endogenous mRNA capping (APExBIO).
• Modified Nucleotides: Incorporation of 5mCTP and ψUTP reduces immune recognition by Toll-like receptors (TLR7, TLR8) and RIG-I-like receptors, thereby decreasing type I interferon response and prolonging mRNA stability (Roach 2024).
• Poly(A) Tail: The presence of a polyadenylated tail (>100 nt) facilitates efficient translation initiation and prevents rapid mRNA degradation.
• Buffer Conditions: The mRNA is supplied at ~1 mg/mL in 1 mM sodium citrate, pH 6.4, an optimal condition for storage and application.

Evidence & Benchmarks

• Cap 1 capping of synthetic mRNA enhances translation efficiency and reduces innate immune activation compared to uncapped or Cap 0 mRNAs (Cell, 2019).
• 5mCTP and ψUTP modifications in mRNA substantially suppress RNA-mediated innate immune responses and increase mRNA stability in mammalian cells (Roach 2024).
• mCherry mRNA (996 nt) encodes a monomeric fluorophore with excitation at 587 nm and emission at 610 nm, suitable for multiplexed fluorescent assays (FPbase).
• Reporter gene mRNAs with Cap 1 and modified nucleotides show improved protein expression and reduced cytotoxicity in nanoparticle delivery applications (Roach 2024).
• Storage at or below −40°C preserves mRNA integrity and translation competency over extended periods (APExBIO).

Applications, Limits & Misconceptions

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is designed for the following research applications:

• Fluorescent Protein Expression: Enables robust visualization of gene expression and subcellular localization in live cells (see expanded discussion). This article details how 5mCTP/ψUTP modifications specifically improve stability over previous formulations.
• Reporter Gene Assays: Facilitates high-sensitivity quantification in molecular and cell biology experiments.
• Nanoparticle Payload Studies: Used in benchmarking delivery systems for mRNA stability and uptake (Roach 2024).
• Molecular Tracking: Suitable for long-term, in vivo imaging and fate-mapping, extending findings from previous product reviews, which focused primarily on in vitro settings.
• Cell Component Localization: The red emission spectrum allows for multiplexing with GFP and other fluorophores.

Common Pitfalls or Misconceptions

• EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is not intended for clinical therapeutic use; it is for research only.
• Suboptimal storage (above −40°C) can compromise mRNA stability and translation efficiency.
• Transfection efficiency relies on the choice of delivery reagent; some nanoparticle systems may not be compatible.
• The product does not confer immune evasion in all cell types; some innate immune responses may still occur.
• The mCherry sequence length (996 nt) only reflects the coding region and does not account for UTRs or poly(A) tail additions in other constructs.

Workflow Integration & Parameters

• Preparation: Thaw on ice and mix gently before use. Avoid repeated freeze-thaw cycles.
• Transfection: Compatible with lipid-based and polymeric transfection reagents; optimal conditions should be empirically determined.
• Concentration: Supplied at ~1 mg/mL; working concentrations for cell transfection typically range from 0.1–2 μg per well (24-well plate format).
• Controls: Include non-modified mRNA and mock transfections to benchmark efficiency and immune activation.
• Storage: Store at −40°C or below. For long-term storage, aliquot to minimize freeze-thaw cycles.

Compared to earlier mCherry mRNA formulations, the R1017 kit offers enhanced immune evasion and stability, as detailed in recent advances articles. This review further clarifies performance in in vivo applications.

Conclusion & Outlook

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) from APExBIO sets a benchmark for robust, long-lived, and low-immunogenicity reporter gene mRNA. Its integration of Cap 1 structure and advanced nucleotide modifications ensures reproducible fluorescent protein expression in a variety of molecular biology workflows (product page). Ongoing research focuses on expanding the utility of such mRNAs for multiplexed imaging and advanced nanoparticle delivery, extending findings from both in vitro and in vivo experimental paradigms.